Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30291735 | 1.00 | DRD1 (0.49) | DRD1HTR2A | |
| SCHEMBL15074809 | 0.87 | DRD1 (0.42) | DRD1HTR2A | |
| SCHEMBL9927291 | 0.77 | HTR2A (0.34) | DRD1HTR2A | |
| SCHEMBL11910663 | 0.76 | DRD1 (0.50) | DRD1HTR2A | |
| SCHEMBL22991302 | 0.74 | DRD1 (0.49) | DRD1HTR2A | |
| SCHEMBL20377698 | 0.74 | DRD1 (0.49) | DRD1HTR2A | |
| SCHEMBL16146962 | 0.74 | DRD1 (0.49) | DRD1HTR2A | |
| SCHEMBL30066730 | 0.74 | DRD1 (0.49) | DRD1HTR2A | |
| SCHEMBL30153513 | 0.74 | DRD1 (0.49) | DRD1HTR2A | |
| SCHEMBL21374252 | 0.74 | DRD1 (0.62) | DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072569-B2 | Normal alpha olefin synthesis using dehydroformylation or dehydroxymethylation | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200331823-A1 | Normal Alpha Olefin Synthesis Using Dehydroformylation or Dehydroxymethylation | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2020-10-22 | — | — | US | disclosed |
| EP-2676963-B1 | NOVEL COMPOUND, NOVEL LIGAND, NOVEL TRANSITION METAL COMPLEXES, AND CATALYSTS CONSISTING OF NOVEL TRANSITION METAL COMPLEXES | UNIV OKAYAMA NAT UNIV CORP (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-8779133-B2 | Compound, novel ligand, novel transition metal complex, and catalyst including novel transition metal complex | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8779133-B2 | Compound, novel ligand, novel transition metal complex, and catalyst including novel transition metal complex | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20120211082-A1 | PHOTOELECTRIC CONVERSION DEVICE AND SOLAR CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2463929-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-7569735-B2 | Reducing esters or lactones with hydrogen gas in presence of ruthenium catalyst; high yield and high catalytic efficiency under an industrially advantageous condition of relatively low hydrogen pressure and low reaction temperature | TAKASAGO INTERNATIONAL (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080228012-A1 | Reducing esters or lactones with hydrogen gas in presence of ruthenium catalyst; high yield and high catalytic efficiency under an industrially advantageous condition of relatively low hydrogen pressure and low reaction temperature | TAKASAGO INTERNATIONAL CORPORATION | 2008-09-18 | — | — | US | disclosed |
| EP-1622855-B1 | CARBONYLATION PROCESS USING METAL-POLYDENTATE LIGAND CATALYSTS | BP CHEM INT LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080228012-A1 | Reducing esters or lactones with hydrogen gas in presence of ruthenium catalyst; high yield and high catalytic efficiency under an industrially advantageous condition of relatively low hydrogen pressure and low reaction temperature | LPXN, LIPE, MLX | DRD1 653/4885HTR2A 2952/4885 |
| US-20200331823-A1 | Normal Alpha Olefin Synthesis Using Dehydroformylation or Dehydroxymethylation | ADH1A, ADH1C, DHPS | DRD1 160/4885HTR2A 1280/4885 |
| US-11072569-B2 | Normal alpha olefin synthesis using dehydroformylation or dehydroxymethylation | ADH1A, ADH1C, DHPS | DRD1 160/4885HTR2A 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.